Grant: Collaborative Health Research Projects
Université de Montréal
$195,861.00
Bringing a Liquid Cornea for treating corneal blindness into the clinic
FY 2020-21
Summary
Going blind is a top fear of most people. Corneal blindness occurs when the transparent front
of the eye loses it clarity due to injury or disease. We have developed a "Liquid Cornea",
which is basically a new way to repair corneas. Instead of relying on transplantation with
donor tissues, which are in severe short supply with Canadian in some provinces waiting 2-3
years for surgery, we propose to fill perforated corneas or corneas needing replacement of
the front tissues by anterior lamellar grafting, with a biomaterials-based formulation made
from collagen-like peptides. However, to make it practical for clinical use, we have to develop
a syringe-like delivery system that would allow the surgeon to mix up the formulation and
apply within minutes. Also, for patients with severe disease/damage, we need to block the
inflammation and scarring in order to restore vision. Our research strategy is to incorporate an
anti-scarring drug that is already successfully tested in clinical trials by our partner Birch
Biomed into our Liquid Cornea and deliver this through our Rapid Reconstitution Delivery
Device (R2D2) and test it in mini-pigs using optical equipment developed with our partner,
WinTerra Global. Successful completion of this project will allow us to apply for regulatory
approval for a first-in-human clinical trial. The use of the Liquid Cornea instead of current
donor tissue transplants will potentially allow for treatment of a significant proportion of the
current 12.7 million patients still awaiting cornea transplantation due to the donor tissue
shortfall. The R2D2 system will potentially allow for treatment of ulcers or perforations in
ophthalmologists' clinics instead of an operating room that is needed for donor
transplantation, resulting in faster healing time for patients and healthcare savings.
Program
Collaborative Health Research Projects
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
549666-2020
Name nom
Griffith, May
Department département
Médecine
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
195861
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
5100
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Cell biology
Research subject fr
Biologie cellulaire
Installment
inst:1 - 2
Partie
2
Nb partie
2
Application title
Bringing a Liquid Cornea for treating corneal blindness into the clinic
Keyword
NSERC
Application summary
Going blind is a top fear of most people. Corneal blindness occurs when the transparent front
of the eye loses it clarity due to injury or disease. We have developed a "Liquid Cornea",
which is basically a new way to repair corneas. Instead of relying on transplantation with
donor tissues, which are in severe short supply with Canadian in some provinces waiting 2-3
years for surgery, we propose to fill perforated corneas or corneas needing replacement of
the front tissues by anterior lamellar grafting, with a biomaterials-based formulation made
from collagen-like peptides. However, to make it practical for clinical use, we have to develop
a syringe-like delivery system that would allow the surgeon to mix up the formulation and
apply within minutes. Also, for patients with severe disease/damage, we need to block the
inflammation and scarring in order to restore vision. Our research strategy is to incorporate an
anti-scarring drug that is already successfully tested in clinical trials by our partner Birch
Biomed into our Liquid Cornea and deliver this through our Rapid Reconstitution Delivery
Device (R2D2) and test it in mini-pigs using optical equipment developed with our partner,
WinTerra Global. Successful completion of this project will allow us to apply for regulatory
approval for a first-in-human clinical trial. The use of the Liquid Cornea instead of current
donor tissue transplants will potentially allow for treatment of a significant proportion of the
current 12.7 million patients still awaiting cornea transplantation due to the donor tissue
shortfall. The R2D2 system will potentially allow for treatment of ulcers or perforations in
ophthalmologists' clinics instead of an operating room that is needed for donor
transplantation, resulting in faster healing time for patients and healthcare savings.